Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 16
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
21 and over
Pharmaceutical / Industry
VEG105192
NCT00334282
2.
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
21 and over
Pharmaceutical / Industry
VEG102616
NCT00244764
Last Modified:
8/7/2007
 
First Published:
2/10/2006
3.
Phase II Study of GW786034 in Patients With Relapsed or Refractory Advanced or Metastatic Soft Tissue Sarcoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Other, Pharmaceutical / Industry
EORTC-62043
GSK-EORTC-62043, EUDRACT-2004-004378-10, NCT00297258
4.
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
21 and over
Pharmaceutical / Industry
VEG20006
NCT00256880
5.
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
21 and over
Pharmaceutical / Industry
104450
VEG104450, NCT00281632
6.
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
21 and over
Pharmaceutical / Industry
VEG20007
NCT00347919
7.
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
21 and over
Pharmaceutical / Industry
VEG105290
NCT00367679
8.
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
VEG105281
NCT00430781
Last Modified:
10/10/2008
 
First Published:
4/2/2007
9.
Phase II Study of Pazopanib Hydrochloride in Patients With Recurrent Glioblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
NABTC-0602
NABTC-06-02, NCT00459381, NCI-07-C-0138
10.
Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
109609
NCT00549328
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute